356 related articles for article (PubMed ID: 12918763)
1. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
2. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-alpha therapy for sight threatening uveitis.
Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
[TBL] [Abstract][Full Text] [Related]
4. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis.
Lee RW; Dick AD
Br J Ophthalmol; 2010 Mar; 94(3):269-70. PubMed ID: 20215370
[No Abstract] [Full Text] [Related]
5. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ocular manifestations of Behçet's disease.
Davatchi F
Adv Exp Med Biol; 2003; 528():487-91. PubMed ID: 12918750
[No Abstract] [Full Text] [Related]
7. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
8. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
9. [Infliximab treatment for Behçet's disease--beginning of the biological drug era].
Namba K
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):85-6. PubMed ID: 20187504
[No Abstract] [Full Text] [Related]
10. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
11. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
[No Abstract] [Full Text] [Related]
12. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
14. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
Kotter I; Deuter C; Stubiger N; Zierhut M
J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
[No Abstract] [Full Text] [Related]
15. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
16. Mimicry between intestinal Behçet's disease and inflammatory bowel disease.
Rodrigues-Pinto E; Magro F; Pimenta S; Guimarães J; Macedo G
J Crohns Colitis; 2014 Jul; 8(7):714-5. PubMed ID: 24389388
[No Abstract] [Full Text] [Related]
17. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
18. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis triggered by infliximab in a patient with Behçet's disease.
Kawazoe Y; Sugita S; Yamada Y; Akino A; Miura K; Mochizuki M
Jpn J Ophthalmol; 2013 Jan; 57(1):95-7. PubMed ID: 23090423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
